retatrutide side effects clinical trial results 2024 2025 Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a Retatrutide: A Triple Agonist Shaping

*Only available if prescribed after an online consultation with a healthcare provider

Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of consistent quality

Novo Nordisk and Eli Lilly, the dominant players in the GLP-1R market, are expected to collectively capture 94 per cent of the projected $142 billion GLP-1R sales by 2030

Explore compounded semaglutide with B6, if approved, plus provider review, delivery, and ongoing support through Brello.

Full Year GLP-1 Tracker | Journey Continues: Set Goals, Track Habits, Capture Trends, Reflect on Progress and Achieve Your Weight Loss Goals